Yesterday evening, Merus, a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), signed a deal with BVF Partners, Aquilo, Sofinnova and LSP on a USD 55.8 million PIPE.
The deal will close later this week. We are roud to have acted as Dutch counsel to Merus, alongside Latham & Watkins.
The NautaDutilh team was led by Paul van der Bijl, with invaluable support from Jules van de Winckel, Philip Silvis and Arief Roelse.
Merus published an official press release on its website.